Trial Profile
Phase III trial of tarafenacin in overactive bladder syndrome.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2013
Price :
$35
*
At a glance
- Drugs Tarafenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Kwang Dong Pharmaceutical; SALVAT
- 11 Apr 2013 New trial record